论文部分内容阅读
目的研究缬沙坦对酒精性肝硬化患者透明质酸(HA)、Ⅲ型前胶原氨基端肽(PⅢNP)、层黏蛋白(LN)、Ⅳ型胶原(Ⅳ-C)的影响及意义。方法 80例酒精性肝硬化患者,随机分为对照组和实验组,各40例。对照组患者采用戒烟、戒酒并口服水飞蓟宾治疗的常规行为治疗,实验组患者在常规行为治疗的基础上采用缬沙坦治疗。治疗3个月,比较两组患者治疗后肝脏硬度及HA、PⅢNP、LN、Ⅳ-C水平,以及不良反应发生情况。结果治疗3个月后,实验组患者肝脏硬度及HA、LN水平均明显低于对照组患者,差异具有统计学意义(P<0.05);两组患者PⅢNP、Ⅳ-C水平比较差异无统计学意义(P>0.05)。实验组患者不良反应发生率为2.5%,明显低于对照组患者的15.0%,差异具有统计学意义(P<0.05)。不良反应经休息后均得以缓解。结论缬沙坦在治疗酒精性肝硬化过程中,能够有效改善患者的临床症状,效果显著,在临床治疗中值得进行推广应用。
Objective To investigate the effect of valsartan on the expression of HA, PⅢNP, LN and Ⅳ-C in patients with alcoholic liver cirrhosis. Methods 80 patients with alcoholic cirrhosis were randomly divided into control group and experimental group, 40 cases each. Patients in the control group were treated with routine behavioral therapy of smoking cessation, alcohol abstinence and oral silybin treatment. Patients in the experimental group were treated with valsartan on the basis of routine behavioral therapy. After 3 months of treatment, the liver hardness, HA, PⅢNP, LN, Ⅳ-C levels and the incidence of adverse reactions in both groups were compared. Results After 3 months of treatment, the liver hardness and the level of HA and LN in the experimental group were significantly lower than those in the control group (P <0.05). There was no significant difference in PⅢNP and Ⅳ-C between the two groups Significance (P> 0.05). The incidence of adverse reactions in the experimental group was 2.5%, which was significantly lower than that in the control group (15.0%), the difference was statistically significant (P <0.05). Adverse reactions were relieved after the rest. Conclusion Valsartan in the treatment of alcoholic liver cirrhosis can effectively improve the patient’s clinical symptoms, the effect is significant, worth in the clinical treatment of the promotion and application.